FR17C1011I2 - PROTEASOME INHIBITORS - Google Patents

PROTEASOME INHIBITORS

Info

Publication number
FR17C1011I2
FR17C1011I2 FR17C1011C FR17C1011C FR17C1011I2 FR 17C1011 I2 FR17C1011 I2 FR 17C1011I2 FR 17C1011 C FR17C1011 C FR 17C1011C FR 17C1011 C FR17C1011 C FR 17C1011C FR 17C1011 I2 FR17C1011 I2 FR 17C1011I2
Authority
FR
France
Prior art keywords
proteasome inhibitors
proteasome
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1011C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38691782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of FR17C1011I1 publication Critical patent/FR17C1011I1/fr
Application granted granted Critical
Publication of FR17C1011I2 publication Critical patent/FR17C1011I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR17C1011C 2007-08-06 2017-04-14 PROTEASOME INHIBITORS Active FR17C1011I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/017440 WO2009020448A1 (en) 2007-08-06 2007-08-06 Proteasome inhibitors

Publications (2)

Publication Number Publication Date
FR17C1011I1 FR17C1011I1 (en) 2017-05-26
FR17C1011I2 true FR17C1011I2 (en) 2018-04-27

Family

ID=38691782

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1011C Active FR17C1011I2 (en) 2007-08-06 2017-04-14 PROTEASOME INHIBITORS

Country Status (33)

Country Link
EP (3) EP2178888B1 (en)
JP (1) JP5261488B2 (en)
KR (6) KR20150010802A (en)
CN (1) CN101772507B (en)
AU (1) AU2007357338B2 (en)
BR (1) BRPI0721905B8 (en)
CA (1) CA2695082C (en)
CY (2) CY1113386T1 (en)
DK (1) DK2178888T3 (en)
EA (1) EA028622B1 (en)
EC (1) ECSP10010015A (en)
ES (1) ES2390606T3 (en)
FR (1) FR17C1011I2 (en)
GE (1) GEP20125599B (en)
HK (2) HK1143595A1 (en)
HR (1) HRP20120745T1 (en)
HU (1) HUS1700018I1 (en)
IL (4) IL203641A (en)
LT (1) LTC2178888I2 (en)
LU (1) LUC00013I2 (en)
MY (1) MY161991A (en)
NL (1) NL300871I2 (en)
NZ (1) NZ582693A (en)
PH (1) PH12014500053B1 (en)
PL (1) PL2178888T3 (en)
PT (1) PT2178888E (en)
RS (1) RS52435B (en)
SG (1) SG10201508712QA (en)
SI (1) SI2178888T1 (en)
TN (1) TN2010000060A1 (en)
UA (1) UA97536C2 (en)
WO (1) WO2009020448A1 (en)
ZA (1) ZA201000348B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576206B2 (en) † 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2006311584B2 (en) 2005-11-09 2012-03-08 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
AU2007261345B2 (en) 2006-06-19 2012-02-23 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20170125413A (en) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
GEP20135847B (en) 2008-06-17 2013-06-10 Millennium Pharm Inc Boronate ester compounds and pharmaceutical compositions containing them
AR075090A1 (en) 2008-09-29 2011-03-09 Millennium Pharm Inc ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
CA2741312C (en) 2008-10-21 2020-10-27 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
TWI504598B (en) 2009-03-20 2015-10-21 Onyx Therapeutics Inc Crystalline tripeptide epoxy ketone protease inhibitors
JP5919196B2 (en) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Use of peptide epoxy ketones for metastasis inhibition
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
SG183843A1 (en) 2010-03-01 2012-10-30 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
EA029521B1 (en) 2010-03-31 2018-04-30 Милленниум Фармасьютикалз, Инк. Derivatives of 1-amino-2-cyclopropylethylboronic acid
JP5944986B2 (en) * 2011-06-22 2016-07-05 セファロン、インク． Proteasome inhibitors and processes for their preparation, purification, and use
EP4144354A1 (en) * 2011-08-30 2023-03-08 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
EP2793900B1 (en) * 2011-12-22 2018-08-22 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
US20140357596A1 (en) * 2012-01-24 2014-12-04 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal cancer
US20160008382A1 (en) * 2012-01-24 2016-01-14 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
JP2015524394A (en) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Prodrugs of peptide epoxyketone protease inhibitors
CN109096370B (en) * 2012-07-26 2022-03-18 圣特莱国际公司 Polypeptide epoxy ketone compound
JP2013006855A (en) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc Proteasome inhibitor
JP6018319B2 (en) * 2012-12-03 2016-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Substituted triazole boronic acid compounds
WO2015051067A1 (en) 2013-10-03 2015-04-09 Millennium Pharmaceuticals, Inc. Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
SG10202003693RA (en) 2014-05-20 2020-05-28 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
MA41555A (en) * 2015-02-17 2017-12-26 Millennium Pharm Inc POLYTHERAPY FOR CANCER TREATMENT
US10144761B2 (en) 2015-06-19 2018-12-04 Hanlin Scientific Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
CN106608883A (en) * 2015-10-21 2017-05-03 北京大学 Synthetic method of proteasome inhibitor MLN9708
WO2017198194A1 (en) * 2016-05-19 2017-11-23 成都奥璟生物科技有限公司 Boronic acid and borate ester compound and applications thereof
CN106008572B (en) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 A kind of dipeptide boronic acid compound and preparation method and purposes
UA124672C2 (en) 2016-06-21 2021-10-27 Оріон Офтальмолоджі Ллс Heterocyclic prolinamide derivatives
JP7164521B2 (en) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー carbocyclic prolinamide derivatives
CN108368134B (en) * 2016-07-25 2019-06-14 深圳市塔吉瑞生物医药有限公司 A kind of substituted boronic acid compounds and the medical composition and its use comprising the compound
TW201831191A (en) * 2017-01-23 2018-09-01 大陸商成都奥璟生物科技有限公司 Novel boric acid derivative and pharmaceutical composition using same
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
CN108794516A (en) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 Boric acid and boric acid ester compound and its preparation method and application
US11414437B2 (en) 2017-07-28 2022-08-16 Chengdu Origin Biotechnology Limited Company Borate compound, and synthesis method therefor and uses thereof
WO2019038406A1 (en) 2017-08-25 2019-02-28 Synthon B.V. Process for making ixazomib or intermediates therefor
JP2018024694A (en) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Proteasome inhibitor
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN115403603A (en) * 2018-09-14 2022-11-29 成都奥璟生物科技有限公司 Boric acid ester medicine and application thereof
CN110357787A (en) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 Yi Shazuo meter synthesising process research
EP4041246A4 (en) * 2019-10-07 2023-11-01 Cornell University Antimicrobial and antiviral effects of c2-c7alkyl boronic acids
CN110950897B (en) * 2019-12-12 2021-05-28 山东大学 Histone deacetylase, protease double-target inhibitor, preparation method and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (en) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin inhibitors
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2435124A1 (en) 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
PT1399468E (en) 2001-05-30 2006-05-31 Novartis Ag 2 - {[N- (2-AMINO-3- (HETEROARIL OR ARIL) PROPIONYL) -AMINOACYL] -AMINO} -ALQUILBORONIC ACID DERIVATIVES
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
TWI345465B (en) * 2003-08-14 2011-07-21 Cephalon Inc Proteasome inhibitors and methods of using the same
UA90108C2 (en) * 2004-03-30 2010-04-12 Мілленніум Фармасьютікалз, Інк. Synthesis of boronic ester and acid compounds
WO2006008660A2 (en) 2004-07-20 2006-01-26 Affinium Pharmaceuticals, Inc. Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
GB0513349D0 (en) 2005-06-29 2005-08-03 Torres Manel Non-woven fabric
AU2006264305B2 (en) 2005-07-05 2012-07-05 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha

Also Published As

Publication number Publication date
CY1113386T1 (en) 2016-06-22
BRPI0721905A2 (en) 2014-02-25
IL242291A (en) 2017-12-31
GEP20125599B (en) 2012-08-10
EA201070247A1 (en) 2010-06-30
KR20170004031A (en) 2017-01-10
AU2007357338B2 (en) 2014-03-20
PT2178888E (en) 2012-10-04
CY2017016I2 (en) 2017-07-12
WO2009020448A1 (en) 2009-02-12
HRP20120745T1 (en) 2012-10-31
LTPA2017010I1 (en) 2017-05-10
SI2178888T1 (en) 2012-11-30
CY2017016I1 (en) 2017-07-12
EP2178888A1 (en) 2010-04-28
DK2178888T3 (en) 2012-10-01
LTC2178888I2 (en) 2018-03-12
EP2527347A1 (en) 2012-11-28
KR20140042933A (en) 2014-04-07
EP3210987A1 (en) 2017-08-30
BRPI0721905B8 (en) 2021-05-25
NL300871I2 (en) 2017-12-07
SG10201508712QA (en) 2015-11-27
LUC00013I2 (en) 2017-06-19
FR17C1011I1 (en) 2017-05-26
CN101772507B (en) 2012-12-12
KR20100059811A (en) 2010-06-04
IL203641A (en) 2015-11-30
ECSP10010015A (en) 2010-04-30
HK1182924A1 (en) 2013-12-13
IL242291A0 (en) 2015-11-30
IL242290A (en) 2017-12-31
CA2695082A1 (en) 2009-02-12
IL242290A0 (en) 2015-11-30
NZ582693A (en) 2012-01-12
ZA201000348B (en) 2011-03-30
AU2007357338A1 (en) 2009-02-12
LUC00013I1 (en) 2017-04-06
PL2178888T3 (en) 2012-11-30
CA2695082C (en) 2015-07-28
CN101772507A (en) 2010-07-07
IL242292A (en) 2017-12-31
KR101831674B1 (en) 2018-02-23
KR20140042932A (en) 2014-04-07
RS52435B (en) 2013-02-28
PH12014500053A1 (en) 2015-03-30
UA97536C2 (en) 2012-02-27
JP5261488B2 (en) 2013-08-14
BRPI0721905B1 (en) 2020-11-17
KR20160040735A (en) 2016-04-14
HK1143595A1 (en) 2011-01-07
KR101474831B1 (en) 2014-12-19
ES2390606T3 (en) 2012-11-14
MY161991A (en) 2017-05-31
HUS1700018I1 (en) 2017-05-29
KR20150010802A (en) 2015-01-28
TN2010000060A1 (en) 2011-09-26
IL242292A0 (en) 2015-11-30
PH12014500053B1 (en) 2015-03-30
EP2178888B1 (en) 2012-07-04
EA028622B1 (en) 2017-12-29
JP2010535759A (en) 2010-11-25

Similar Documents

Publication Publication Date Title
FR17C1011I2 (en) PROTEASOME INHIBITORS
CY2020023I1 (en) BETA-LACTAMAS INHIBITORS
BRPI0807547A2 (en) HYPERCYCLIC ASPARTIL PROTEASE INHIBITORS
CR10831A (en) ESPIRO KETONA ACETIL-CoA CARBOXILASA INHIBITORS
DK2041138T3 (en) PYRROLTRIAZINKINASE INHIBITORS
DK2024375T3 (en) Cyclopropyl-condensed indolobenzazepine-HCV-NS5B inhibitors
BRPI0810365A2 (en) INDOL 7-REPLACED MLC-1 INHIBITORS
IT1394247B1 (en) TIGHTENING DEVICE
BRPI0814797A2 (en) DNA-PK INHIBITORS
BRPI0807772A2 (en) PACKING DEVICE
BRPI0918564A2 (en) inhibitors
BRPI0912234A2 (en) salinosporamide derivatives as proteasome inhibitors
FI20085565A (en) sealing device
AT506380A3 (en) STAMP DEVICE
DE602009001221D1 (en) sealing device
DK2066662T3 (en) SERINHYDROLASE INHIBITORS
BRPI0918966A2 (en) protease inhibitors
NO20070960A (en) Teine
BRPI0919073A2 (en) protease inhibitors
GB0707315D0 (en) Novel proteasome inhibitor
FI20075320A0 (en) New useful inhibitors
ITMI20061754A1 (en) PERFORMED BEVELING DEVICE